Research Notes

Stay informed with the most recent market and company research insights.

A man sitting at a table with a glass of orange juice.

Research Notes

Activity air-pocket, with strong long-run demand

Brickworks
3:27pm
March 21, 2024
BKW continues to paint a relatively sanguine picture, with building products expected to see some short-term weakness. The property portfolio has declined in value as a result of a 100bps increase in cap rates to 5.1%, despite continued strength across the underlying operating markets. Longer term, management remains firmly of the opinion that Australia is on the cusp of a property boom, with record immigration levels and population growth exacerbating an already chronic housing undersupply issue. The industrial portfolio is expected to continue growing rental income, with the business outlining a path to double rent through continued development and passing rental growth. Our view remains largely unchanged, with the short to medium outlook remaining relatively soft, which will see the group strategy shifting from investment to cashflow generation. This sees modest earnings growth through FY25, hence our Hold recommendation.

No surprises ... now a waiting game for ACCC decision

Sigma Healthcare Ltd
3:27pm
March 21, 2024
SIG posted its FY24 result which came in at the top end of EBIT guidance (pre-merger costs of $8.2m). As we expected there was limited commentary around the ACCC process, with SIG making its submission in February and public consultation starting from 8 March. We don’t expect a decision until the end of CY24. Given our view on the timing of the ACCC announcement we have delayed the incorporation of the CWG business into our model by six months. After rolling our model forward and including CWG from 31 January 2025 our target price has increased to $1.14 (was $1.07). As the share price is within 10% of the new target we move to a Hold (previously Add) recommendation.

Growing the Swiss footprint

Sonic Healthcare
3:27pm
March 20, 2024
Sonic Healthcare (SHL) is acquiring Switzerland-based Dr Risch laboratory group (Dr Risch) for CHF117m (A$202m), including CHF30m (A$52m) in scrip, with the balance funded via existing CHF cash and debt. Dr Risch employs c650 staff across 13 laboratories and has a lab in Liechtenstein, with a full-range offering of routine and specialty laboratory testing and combined annual turnover of cCHF102m (cA$176m). The deal is expected to close by 31 Mar-24, with the transaction EPS accretive from CY25 and ROIC positive once synergies from multiple areas of infrastructure and operations are achieved. We have adjusted FY24-26 estimates, with our target price increasing to A$34.94 (from A$34.05). Add rating maintained.

+50% margins through the cyclical low ain’t bad

New Hope Group
3:27pm
March 19, 2024
Another typically solid 1H result from NHC with few surprises outside of the dividend which beat our cautious estimate. All guidance was re-affirmed, with higher volumes to support 2H cost reduction. NHC’s defensive attributes – cash margins, balance sheet, steady dividends – appear to support lower volatility relative to more leveraged peers. Maintain Hold as NHC trades within 10% of fair value. A forecast 7-8% yield offers solid compensation as investors await the next upswing.

Putting the customer first

Myer
3:27pm
March 18, 2024
Myer Holdings (ASX: MYR) operates the largest chain of premium and mid-range department stores in Australia. The business was founded 124 years ago, but even after the emergence of the suburban shopping centre and the rise of multicategory ecommerce sites, Myer has managed not just to remain relevant but is performing strongly on an active program of reinvention. Sales last year were the highest since 2005, underpinned by over 20% online penetration and more than 4m active members in its loyalty program. The balance sheet is in good shape with over $200m in net cash (excluding leases) and Myer is back to paying dividends. A new CEO, Olivia Wirth, takes the reins in June, looking to replicate with MYER one her success with the Qantas Frequent Flyer loyalty program.

Re-basing expectations

True North Copper
3:27pm
March 15, 2024
The CCP mining study details a value accretive project offering material positive cash flows from late 2024. The mining re-start will now mobilise. Execution of the CCP re-start to plan is company-defining in 2024 as TNC has an opportunity to achieve self-funding status and allay market fear of liquidity risk. We think the current share price ascribes no value to the CCP’s 4.6 year reserves, projected cash flows or mine life upside. Upside leverage to execution success is significant. Mt Oxide’s true blue-sky potential also appears overlooked. Potential returns from 8cps are substantial although we think investors do require greater risk tolerance. Demonstrating commerciality late 2024 is key.

Updating for Q1, Suncorp Bank, and 16.5% AmBank

ANZ Banking Group
3:27pm
March 14, 2024
We update our modelling for Q1 performance, inclusion of Suncorp Bank acquisition (given completion looks increasingly likely), and sale of 16.5% AmBank. Meaningful forecast upgrades because of incremental earnings from the SB acquisition now included in our modelling. We forecast earnings decline in FY24F while assumed full year inclusion of SB helps alleviate further declines in FY25F. 12 month target price lifts 9% to $26.83/sh. HOLD retained at current prices.

Implements on market buyback

Clinuvel Pharmaceuticals
3:27pm
March 14, 2024
CUV have announced an on-market buy back of approximately 3% of the shares on issue. We had been calling out for capital management and viewed this was necessary given the significant cash stockpile whilst sitting on multi-year lows. While several issues continue to present an overhang for the stock in our view, we view this as a step in the right direction. We make no changes to our valuation at this stage however given the weakness following our last note, we move back to an Add recommendation.

Heading in the right direction

Australian Vintage
3:27pm
March 12, 2024
AVG saw a material improvement in profitability during the 1H24 with underlying EBITS up 59.9% on the pcp and 41% ahead of our forecast. FY24 guidance was reiterated with AVG expecting underlying EBITDAS to be directionally aligned with FY22 reflecting easing inflation and its cost out program. We recently upgraded our recommendation for AVG to an ADD on the view that it would deliver a material earnings recovery through FY24/25. Pleasingly, AVG’s 1H24 performance demonstrates that our investment thesis remains intact and if management continues to execute there is material upside potential on offer. A decision on the China wine tariffs and any corporate activity (e.g. recently confirmed in early talks with Accolade to merge), are key near-term share price catalysts.

Waiting for reasons to upgrade

Proteomics International Laboratories
3:27pm
March 11, 2024
Following a strong run over the last month, our target price range has now been reached. At the risk of going against clear share price momentum, we continue to wait for further detail on initial launch of the PromarkerD but also note our valuation only assumes commercial success in the US. Significant upside potential remains as the rollout progresses in the US and other jurisdictions, but also view the endometriosis and oesophageal cancer diagnostics will remain key and likely hold significant value with licensing opportunities. We maintain our target price of A$1.38, but our recommendation reduces to a Hold recommendation (from Speculative Buy).

News & Insights

Michael Knox, Chief Economist looks at what might have happened in January 2026 if the cuts in corporate tax rates in Trumps first term were not renewed and extended in the One Big Beautiful Bill

In recent weeks, a number of media commentators have criticized Donald Trump's " One big Beautiful Bill " on the basis of a statement by the Congressional Budget Office that under existing legislation the bill adds $US 3.4 trillion to the US Budget deficit. They tend not to mention that this is because the existing law assumes that all the tax cuts made in 2017 by the first Trump Administration expire at the end of this year.

Let’s us look at what might have happened in January 2026 if the cuts in US corporate tax rates in Trumps first term were not renewed and extended in the One Big Beautiful Bill.

Back in 2016 before the first Trump administration came to office in his first term, the US corporate tax rate was then 35%. In 2017 the Tax Cut and Jobs Act reduced the corporate tax rate to 21%. Because this bill was passed as a "Reconciliation Bill “, This meant it required only a simple majority of Senate votes to pass. This tax rate of 21% was due to expire in January 2026.

The One Big Beautiful Bill has made the expiring tax cuts permanent; this bill was signed into law on 4 July 2025. Now of course the same legislation also made a large number of individual tax cuts in the original 2017 bill permanent.

What would have happened if the bill had not passed. Let us construct what economists call a "Counterfactual"

Let’s just restrict ourselves to the case of what have happened in 2026 if the US corporate tax had risen to the prior rate of 35%.

This is an increase in the corporate tax rate of 14%. This increase would generate a sudden fall in US corporate after-tax earnings in January 2026 of 14%. What effect would that have on the level of the S&P 500?

The Price /Earnings Ratio of the S&P500 in July 2025 was 26.1.

Still the ten-year average Price/ Earnings Ratio for the S&P500 is only 18.99. Let’s say 19 times.

Should earnings per share have suddenly fallen by 14%, then the S&P 500 might have fallen by 14% multiplied by the short-term Price/ Earnings ratio.

This means a likely fall in the S&P500 of 37%.

As the market recovered to long term Price Earnings ratio of 19 this fall might then have ben be reduced to 27%.

Put simply, had the One Big, beautiful Bill not been passed, then in 2026 the US stock market might suddenly have fallen by 37% before then recovering to a fall of 27% .

The devastating effect on the US and indeed World economy might plausibly have caused a major recession.

On 9 June Kevin Hassert the Director of the National Economic Council said in a CBS interview with Margaret Brennan that if the bill did not pass US GDP would fall by 4% and 6-7 million Americans would lose their jobs.

The Passage of the One Big Beautiful Bill on 4 July thus avoided One Big Ugly Disaster.

Read more
On 7 July the AFR published a list of 37 Economists who had answered a poll on when the RBA would next cut rates. 32 of them thought that the RBA would cut on 8 July. Only 5 of them did not believe the RBA would cut, Michael Knox being one of them.

On 7 July the AFR published a list of 37 Economists who had answered a poll on when the RBA would next cut rates. 32 of them thought that the RBA would cut on 8 July. Only 5 of them did not believe the RBA would cut on 8 July. I was one of them. The RBA did not cut.

So today I will talk about how I came to that decision. First, lets look at our model of official interest rates. Back in January 2015 I went to a presentation in San Franciso by Stan Fishcer . Stan was a celebrated economist who at that time was Ben Bernanke's deputy at the Federal Reserve. Stan gave a talk about how the Fed thought about interest rates.

Stan presented a model of R*. This is the real short rate of the Fed Funds Rate at which monetary policy is at equilibrium. Unemployment was shown as a most important variable. So was inflationary expectations.

This then logically lead to a model where the nominal level of the Fed funds rate was driven by Inflation, Inflationary expectations and unemployment. Unemployment was important because of its effect on future inflation. The lower the level of unemployment the higher the level of future inflation and the higher the level of the Fed funds rate. I tried the model and it worked. It worked not just for the Fed funds rate. It also worked in Australia for Australian cash rate.

Recently though I have found that while the model has continued to work to work for the Fed funds rate It has been not quite as good in modelling that Australian Cash Rate. I found the answer to this in a model of Australian inflation published by the RBA. The model showed Australian Inflation was not just caused by low unemployment, It was also caused by high import price rises. Import price inflation was more important in Australia because imports were a higher level of Australian GDP than was the case in the US.

This was important in Australia than in the US because Australian import price inflation was close to zero for the 2 years up to the end of 2024. Import prices rose sharply in the first quarter of 2025. What would happen in the second quarter of 2025 and how would it effect inflation I could not tell. The only thing I could do is wait for the Q2 inflation numbers to come out for Australia.

I thought that for this reason and other reasons the RBA would also wait for the Q2 inflation numbers to come out. There were other reasons as well. The Quarterly CPI was a more reliable measure of the CPI and was a better measure of services inflation than the monthly CPI. The result was that RBA did not move and voiced a preference for quarterly measure of inflation over monthly version.

Lets look again at R* or the real level of the Cash rate for Australia .When we look at the average real Cash rate since January 2000 we find an average number of 0.85%. At an inflation target of 2.5 % this suggests this suggest an equilibrium Cash rate of 3.35%

Model of the Australian Cash Rate.
Model of the Australian Cash Rate


What will happen next? We think that the after the RBA meeting of 11 and 12 August the RBA will cut the Cash rate to 3.6%

We think that after the RBA meeting of 8 and 9 December the RBA will cut the Cash rate to 3.35%

Unless Quarterly inflation falls below 2.5% , the Cash rate will remain at 3.35% .

Read more
Investment Watch is a quarterly publication for insights in equity and economic strategy. Recent months have been marked by sharp swings in market sentiment, driven by shifting global trade dynamics, geopolitical tensions, and policy uncertainty.

Investment Watch is a quarterly publication produced by Morgans that delves into key insights for equity and economic strategy.

This publication covers

Economics - 'The challenge of Australian productivity' and 'Iran, from the Suez blockade to the 12 day war'
Asset Allocation
- 'Prioritise portfolio resilience amidst the prevailing uncertainty'
Equity Strategy
- 'Rethinking sector preferences and portfolio balance'
Fixed Interest
- 'Market volatility analysis: Low beta investment opportunities'
Banks
- 'Outperformance driving the broader market index'
Industrials
- 'New opportunities will arise'
Resources and Energy
- 'Getting paid to wait in the majors'
Technology
- 'Buy the dips'
Consumer discretionary
- 'Support remains in place'
Telco
- 'A cautious eye on competitive intensity'
Travel
- 'Demand trends still solid'
Property
- 'An improving Cycle'

Recent months have been marked by sharp swings in market sentiment, driven by shifting global trade dynamics, geopolitical tensions, and policy uncertainty. The rapid pace of US policy announcements, coupled with reversals, has made it difficult for investors to form strong convictions or accurately assess the impact on growth and earnings. While trade tariffs are still a concern, recent progress in US bilateral negotiations and signs of greater policy stability have reduced immediate headline risks.

We expect that more stable policies, potential tax cuts, and continued innovation - particularly in AI - will support a gradual pickup in investment activity. In this environment, we recommend prioritising portfolio resilience. This means maintaining diversification, focusing on quality, and being prepared to adjust exposures as new risks or opportunities emerge. This quarter, we update our outlook for interest rates and also explore the implications of the conflict in the Middle East on portfolios. As usual, we provide an outlook for the key sectors of the Australian market and where we see the best tactical opportunities.


Morgans clients receive exclusive insights such as access to our latest Investment Watch publication. Contact us today to begin your journey with Morgans.

      
Contact us
      
      
Find an adviser
      
Read more